Logout
If you want to log out click in LogOut
Langerhans Cell Histiocytosis (LCH) is a rare disorder marked by the excessive proliferation of Langerhans cells, a type of dendritic cell involved in immune responses. These cells normally play a role in detecting pathogens, but in LCH, they accumulate and form lesions in various organs, including the skin, bones, liver, and lungs. The condition exhibits a range of severity, from isolated lesions to multi-organ involvement, and can affect both children and adults.
AnyGenes offers specialized qPCR arrays that allow for in-depth profiling of key signaling pathways and gene expression patterns involved in Langerhans Cell Histiocytosis. Researchers can use these tools to analyze biomarkers associated with immune response, cell proliferation, and differentiation. By utilizing AnyGenes arrays, scientists gain a comprehensive understanding of the molecular underpinnings of LCH, leading to more precise diagnostics and the identification of potential therapeutic targets.
LCH lesion composition. The composition of LCH lesions is very heterogenous with the presence of different components of the immune system. Crosstalk between the LCH cells and the infiltrating immune cells contributes to the formation of a highly inflammatory and dysfunctional microenvironment that inhibits the clearance of the LCH cells by the immune cells and favors their persistence and survival in the lesions.
The progression of LCH is closely tied to dysregulated signaling pathways. Key pathways such as the MAPK (Mitogen-Activated Protein Kinase) signaling pathway and RAF/MEK/ERK pathway have been found to be critical in the development of LCH. Mutations in genes like BRAF are often implicated, leading to abnormal cell growth and proliferation. Some of the other notable biomarkers: S100 protein, CD1a, Langerin (CD207) and CSF1R. The histological examination reveals characteristic features such as: Birbeck Granules and Granulomatous Infiltrates.
Symptoms of LCH can vary widely based on the organs affected:
The immune response in LCH is complex and involves various immune cell types:
Given the central role of the MAPK and PI3K-AKT pathways in LCH, these signaling cascades represent promising therapeutic targets. Inhibitors of BRAF, such as vemurafenib, have shown efficacy in treating LCH patients with the BRAF V600E mutation.
Other potential therapeutic targets include MEK inhibitors, which target downstream components of the MAPK pathway, and PI3K inhibitors. Combination therapies that target multiple pathways simultaneously are also being explored to improve treatment outcomes and reduce the likelihood of resistance.
Customize your own signaling pathways (SignArrays®) with the factors of your choice!
Simply download and complete our Personalized SignArrays® information file
and send it at
contact@anygenes.com
to get started on your project.
| Signaling Pathways | Product ref | Informations |
|---|---|---|
|
Langerhans Cell Histiocytosis |
LCH1H1 |
|
|
Langerhans Cell Histiocytosis |
LCH2H1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
|
Langerhans Cell Histiocytosis |
LCH1M1 |
| Signaling Pathways | Product ref | Informations |
|---|---|---|
|
Langerhans Cell Histiocytosis |
******* |
|
| Signaling Pathways | Product ref | Informations |
|---|---|---|
|
Langerhans Cell Histiocytosis |
******* |
|